Rhone-Poulenc Taxotere, Campto Propel Oncology Sales To 39% Growth
Executive Summary
Sales of Rhone-Poulenc's Taxotere (docetaxel) jumped 40.9% (excluding the impact of exchange rates) to $116 mil. in the second quarter, leading the firm's oncology revenues.